NCT00732641View on ClinicalTrials.gov

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

PHASE3CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Peginterferon

Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00732641 - Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | Biotech Hunter | Biotech Hunter